MNOVNasdaqPharmaceutical PreparationsFiscal year ends December 31
MEDICINOVA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.40−0.02 (-1.41%)
Close on Oct 19, 2026
- Market cap
- $68.91M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-3242.5%
Net margin
-2928.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -32.3% | -18.9% | -25.5% | |
| Return on assets | -28.0% | -17.9% | -23.6% | |
| Current ratio | 15.16 | 27.67 | 8.16 | |
| Interest coverage | -23968.8× | – | – | |
| Capex to revenue | – | – | 0.7% | |
| Diluted shares | 33M | 44M | 49M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Medicinova generated $50.18M from operations and spent $58.84K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$50.18M
Used
$58.84K
Capital expenditure$58.84K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2928.8%
×Asset turnover0.01×
×Equity multiplier1.08×
=Return on equity, FY2025-25.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2928.8% | 0.01× | 1.08× | -25.5% |
| FY2023 | -857.2% | 0.01× | 1.06× | -12.9% |
| FY2021 | -251.0% | 0.05× | 1.05× | -13.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$12.00M
- Cash generatingOperating cash flow above zero-$9.81M
- Return on assets improvedROA up on the prior year-16.7% → -21.5%
- Earnings backed by cashOperating cash flow above net income-$9.81M vs -$12.00M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose13.88 → 8.16
- No dilutionShare count did not rise49M → 49M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → 0.01